---
document_datetime: 2025-09-11 17:21:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/otulfi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: otulfi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.7878712
conversion_datetime: 2025-12-27 14:01:27.994735
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Otulfi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001/G            | This was an application for a group of variations. Type II - B.II.e.1.b.2 - Change in the immediate packaging of the sterile biological finished product Otulfi to add a new container (vial) for the 90 mg/mL solution for injection (EU/1/24/1863/004). Type II - B.II.b.3.c - Changes in the manufacturing | 10/04/2025                          |                                             | SmPC, Labelling and PL           | The SmPC has been updated to reflect the new new 45 mg vial presentation for subcutaneous injection, including a new Table 2 weight-based dosage calculations for patients < 60 kg in SmPC section 4.2 in line with the reference medicinal product. The Labelling and PL have been updated accordingly. The RMP is updated consequentially to include the information specific to the new PFS presentation and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| process of the biological consequential changes in manufacturing process due container (vial). Type IB - B.II.d.1.z - To specifications (appearance, container closure integrity) the finished product. Type IAIN - B.II.b.1.a - Austria GmbH, Am Gewerbepark as an alternative site responsible packaging of the finished solution for injection in Module 3 have been updated, overarching Module 2 and submitted for the vial dosage The product information updated consequentially specific to the new 45 mg a new Table 2 weight-based patients < 60 kg in SmPC reference medicinal product, changes. The requested group of amendments to the Summary Characteristics, Labelling, A and to the Risk Management B.II.b.3.c - Change in the   | some editorial changes (final version 1.2).   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | a biological/immunological medicinal product and the change requires an assessment of comparability B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products   |            |             |                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0003/G | This was an application for a group of variations. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH      | 13/01/2025 | SmPC and PL | To update section 4.4 of the SmPC to remove the wording `non-melanoma' from the safety information on malignancies, following the assessment of the same change for the reference product. To update sections 4.4, 4.5 and 4.6 of the SmPC and section 2 of the PL to revise a warning on administration of live vaccines in infants exposed to ustekinumab in utero. The RMP is updated accordingly. |
| IB/0002   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                           | 18/12/2024 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                       |